CLBT Relative Valuation
CLBT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLBT is overvalued; if below, it's undervalued.
Historical Valuation
Cellebrite DI Ltd (CLBT) is now in the Fair zone, suggesting that its current forward PE ratio of 30.22 is considered Fairly compared with the five-year average of 46.91. The fair price of Cellebrite DI Ltd (CLBT) is between 12.29 to 31.11 according to relative valuation methord.
Relative Value
Fair Zone
12.29-31.11
Current Price：14.30
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
9.48
P/B
Median3y
9.75
Median5y
4.79
3.93
FCF Yield
Median3y
3.06
Median5y
3.54
Competitors Valuation Multiple
The average P/S ratio for CLBT's competitors is 6.21, providing a benchmark for relative valuation. Cellebrite DI Ltd Corp (CLBT) exhibits a P/S ratio of 6.85, which is 10.25% above the industry average. Given its robust revenue growth of 20.06%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Cellebrite DI Ltd (CLBT) currently overvalued or undervalued?
What is Cellebrite DI Ltd (CLBT) fair value?
How does CLBT's valuation metrics compare to the industry average?
What is the current P/B ratio for Cellebrite DI Ltd (CLBT) as of Jul 18 2025?
What is the current FCF Yield for Cellebrite DI Ltd (CLBT) as of Jul 18 2025?
What is the current Forward P/E ratio for Cellebrite DI Ltd (CLBT) as of Jul 18 2025?